Ten-year follow-up of a phase 2 study of
β
Gisele A. Sarosy; Mahrukh M. Hussain; Michael V. Seiden; Arlan F. Fuller; Najmos
π
Article
π
2010
π
John Wiley and Sons
π
English
β 148 KB
π 1 views
## Abstract ## BACKGROUND: The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advancedβstage epithelial ovarian cancer (EOC) who were receiving doseβintense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing sched